Armata Pharmaceuticals (ARMP) Short term Debt (2018 - 2025)
Quarterly results put Short term Debt at $48.1 million for Q3 2025, up 16.28% from a year ago — trailing twelve months through Sep 2025 was $48.1 million (up 16.28% YoY), and the annual figure for FY2020 was $1.9 million, up 100.0%.
Armata Pharmaceuticals has reported Short term Debt over the past 5 years, most recently at $48.1 million for Q3 2025.
- Short term Debt reached $48.1 million in Q3 2025 per ARMP's latest filing, up from $33.4 million in the prior quarter.
- Across five years, Short term Debt topped out at $71.7 million in Q1 2024 and bottomed at $27.7 million in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Armata Pharmaceuticals | 301.92 Mn | 297.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 48.09 Mn |
| Jun 30, 2025 | 33.45 Mn |
| Mar 31, 2025 | 27.69 Mn |
| Sep 30, 2024 | 41.36 Mn |
| Jun 30, 2024 | 48.26 Mn |
| Mar 31, 2024 | 71.66 Mn |
| Dec 31, 2020 | 1.94 Mn |
| Sep 30, 2020 | 1.77 Mn |
| Jun 30, 2020 | 1.62 Mn |
| Mar 31, 2020 | 1.48 Mn |
| Dec 31, 2019 | 970,000.00 |
| Sep 30, 2019 | 885,000.00 |
| Jun 30, 2019 | 769,000.00 |
| Dec 31, 2018 | 970,000.00 |